Cobimetinib Sensitizes Cervical Cancer to Paclitaxel via Suppressing Paclitaxel-Induced ERK Activation.

Liu, Yuan; Zhao, Runsheng; Qin, Xiaomin; Mao, Xiaogang; Li, Quan; Fang, Shanshan

Liu, Yuan; Zhao, Runsheng; Qin, Xiaomin; Mao, Xiaogang; Li, Quan; Fang, Shanshan.

Afiliação

Liu Y; Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Zhao R; Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Qin X; Department of Obstetrics and Gynecology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Mao X; Department of Obstetrics and Gynecology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Li Q; Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Fang S; Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.

Pharmacology ; 107(7-8): 398-405, 2022.

Article em En | MEDLINE | ID: mdl-35526525

Assuntos

Azetidinas; Neoplasias do Colo do Útero; Animais; Apoptose; Azetidinas/farmacologia; Azetidinas/uso terapêutico; Linhagem Celular Tumoral; Feminino; Humanos; Camundongos; Paclitaxel/farmacologia; Piperidinas/farmacologia; Piperidinas/uso terapêutico; Neoplasias do Colo do Útero/tratamento farmacológico; Neoplasias do Colo do Útero/metabolismo

Palavras-chave

Cervical cancer; Cobimetinib; MAPK/ERK; Paclitaxel

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Neoplasias do Colo do Útero Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google